Advances in Neurofibromatosis: Integrating Multi-modality Therapy

This live virtual conference is intended to provide an update on current evaluation and multi-modality therapy for neurofibromatosis.

Neurofibromatosis represents a group of inheritable disorders that require multi-disciplinary integrated care. Major advances in defining molecular alterations and developing targeted therapies have changed the landscape of treatment, but require continued laboratory and clinical investigations. Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) are pursuing numerous areas of investigation in the clinic and laboratory and we anticipate will become one of the driving forces in the development of newer therapies for both benign and malignant tumors (eg MPNST) in NF-associated tumors. Additionally, MSK is one of the most active surgical groups in the world with the recent integration of advanced technologies such as DaVinci robot resection of paraspinal benign tumors.

1. Learn recent NF clinical and research advancements
2. Develop a basic understanding of the pathophysiology of NF1, NF2 and SWN
3. Review clinical symptoms and imaging typical of patients with NF1, NF2 and SWN
4. Discuss therapeutic options for NF1 associated plexiform neurofibroma, including targeted therapy
5. Learn about pre-clinical models for NF1, which serve as a springboard for future clinical trials
6. Learn about clinical trial options for patients with NF1 associated MPNST
7. Learn about NF1 associated GIST, NF1 associated breast cancer, NF1 associated long bone dysplasias
8. Discuss therapeutic options for NF2 associated vestibular schwannoma, including targeted therapy, radiation and surgical resection
9. Discuss symptomatic treatment for Schwannomatosis, including pain control, radiation and surgical resection

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. Visit our Help page for more information.

By registering for the live virtual course, you will be able to view presentations, hear live audio, and interact online. All sessions presented live on Friday, October 9, 2020, will be recorded and made available to attendees for viewing after the course. CME credit will be offered for this course and a certificate will be available after a post-course evaluation is complete. This live virtual course will be delivered using Zoom. We encourage all attendees to download the Zoom app prior to the start of the course (zoom.us/download). Additional access details will be emailed to all attendees before the course.

Registration Discounts/Promotions

• MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact [email protected] for more information.
• MSK employee registration is complimentary. However, you must complete course registration in order to attend this course. If you are registered for this course and are unable to attend, please email [email protected].

Please note that after your payment has been processed, no further promotional discount adjustments will be made to your registration.

Cancellation Policy

If you cancel your participation in this course, your registration fee, less a $25 administrative fee, will be refunded when email notification is received by the MSK Office of Continuing Medical Education (MSK CME) at least 7 days prior to the first day of the course ([email protected]).

Cancellations or no-shows after this date are not eligible for a refund. MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, we will refund the registration fee in full, but are not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies. At any time, you may substitute another registrant in your place after contacting MSK CME with the relevant information.

Please note if it has been more than 120 days since you paid for a course, or submitted a check for payment, a W9 form will need to be completed for us to refund your registration. You will not be taxed on your refund.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MSK Course Directors

Mark Bilsky, MD
Attending Neurosurgeon
Chief, Multi-Disciplinary Spine Tumor Service

Matthias Karajannis, MD, MS
Chief, Pediatric Neuro-Oncology Service

Ori Barzilai, MD
Assistant Attending Neurosurgeon

Anna Piotrowski, MD
Assistant Attending Neuro-Oncologist

MSK Course Faculty

Edmund Bartlett, MD
Assistant Attending Surgeon

Aimee Crago, MD, PhD 
Associate Attending Surgeon

Amitabh Gulati, MD
Associate Attending Physician
Director, Chronic Pain

Jonathan Landa, DO
Associate Attending Radiologist

Luis Parada, PhD
Director, Brain Tumor Center

Daniel Prince, MD, MPH
Assistant Attending Surgeon
  
Samuel Selesnick, MD
Attending Surgeon (WCMC, MSK)
Vice Chairman, Department of Otolaryngology – Head & Neck Surgery
  
William Tap, MD
Chief, Sarcoma Medical Oncology Service

Michael Walsh, MD
Assistant Attending Geneticist and Pediatric Oncologist
  
Yoshiya (Josh) Yamada, MD
Attending Radiation Oncologist

Faculty Disclosures

Friday, October 9, 2020